Analysts are also concerned about the lack of optimism in the management's commentary on margins improving.

Gland Pharma's rebound comes after the stock had lost close to 39 percent in the past five sessions.

Kokuyo Camlin shares rallied more than 14 percent to Rs 110.50 with significantly higher volumes on the NSE.

The drugmaker's net profit for the quarter plummeted to Rs 78.6 crore due to high base on account of COVID sales and a shutdown of production line in the Pashamylaram Penems facility for line upgradation.

YES Securities is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 1720 in its research report dated January 23, 2023.

Motilal Oswal is bullish on Gland Pharma recommended buy rating on the stock with a target price of Rs 1700 in its research report dated January 23, 2023.

Gland Pharma Q3: Revenue from operations for the quarter at Rs 938 crore declined 12% compared to year-ago period.

Net Sales are expected to increase by 0.6 percent Y-o-Y (up 2.4 percent Q-o-Q) to Rs 10,696 crore, according to Nirmal Bang.

Sharekhan recommended Hold rating on Gland Pharma with a target price of Rs 1689 in its research report dated December 29, 2022.

China is a very different economy and its vaccination coverage is lower while infection rate is higher than India's, says Balasubramanian

As per BSE filing, Fosun International has a controlling stake of 57.86 percent in Hyderabad-based Gland Pharma

Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 2260 in its research report dated November 30, 2022.

Gland Pharma’s management expects to close the transaction by February/March 2023 and to fund the deal through internal accruals

Gland Pharma’s earnings for the September quarter have also done little to ease investors’ anxiety given that the company reported a sharp decline in net profit

Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 2260 in its research report dated October 27, 2022.

Gland Pharma jumped 5.6 percent to Rs 2,501 and formed small bodied bullish candle on the daily scale, while Schneider Electric Infrastructure climbed over 6 percent to Rs 145.3 and Inverted Hammer kind of pattern on the daily charts with above average volumes.

Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3080 in its research report dated July 20, 2022.

Motilal Oswal is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3700 in its research report dated June 25, 2022.

The brokerage firm expects Gland Pharma to deliver 15-20 percent growth in revenues over the next three years

Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3770 in its research report dated May 20, 2022.

Menu Private Limited sold all its 5,05,504 equity shares in Barbeque at an average price of Rs 1,163 apiece. The stock on April 21 rose 1.4 percent to Rs 1,178.